ArticleExpert opinion on investigational drugs2015
Investigational drugs for visceral leishmaniasis.
Article in Expert opinion on investigational drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 54 citations in OpenAlex.
- Review on macrophage polarization during visceral leishmaniasis and impact of glycoprotein.Glycoconjugate journal · 2026Review
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Long-term hematopoietic stem cells as a parasite niche during treatment failure in visceral leishmaniasis.Communications biology · 2022Article
- Long non-coding RNAs as possible therapeutic targets in protozoa, and in Schistosoma and other helminths.Parasitology research · 2022Review
- Efficient antileishmanial activity of amphotericin B and piperine entrapped in enteric coated guar gum nanoparticles.Drug delivery and translational research · 2021Article
- Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.Parasitology research · 2021Article
- Chiral Cyclobutane-Containing Cell-Penetrating Peptides as Selective Vectors for Anti-International journal of molecular sciences · 2020Article
- Cell death pathways in pathogenic trypanosomatids: lessons of (over)kill.Cell death & disease · 2019Review
- Review
- Activity of the antiarrhythmic drug amiodarone againstThe journal of venomous animals and toxins including tropical diseases · 2018Article
- 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.Journal of medicinal chemistry · 2017Article
- Nanostructured delivery systems with improved leishmanicidal activity: a critical review.International journal of nanomedicine · 2017Review
- Recent developments and future prospects in the treatment of visceral leishmaniasis.Therapeutic advances in infectious disease · 2016Review
- The Antileishmanial Potential of C-3 Functionalized Isobenzofuranones against Leishmania (Leishmania) Infantum Chagasi.Molecules (Basel, Switzerland) · 2015Article
- SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.Bioorganic & medicinal chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed using PubMed. The article specifically looks at investigational drugs, which have demonstrated, at the very least, in vitro and in vivo activities against the leishmania species that cause visceral leishmaniasis. Specifically, the authors review the nitroimidazole compound fexinidazole, which is one of the few drugs which have reached Phase II trials. The article also discusses the R enantiomer of (S)-PA-824, which has shown good antileishmanial activity. Finally, the article also highlights the many novel delivery systems and oral formulations of amphotericin B, which are both cheap and less toxic and are currently under investigation. Expert opinion: Very few new drugs have reached the clinic for this neglected tropical disease and there is an urgent need for new efficacious therapeutics. The authors believe that support from public-private partnerships would help in enabling the prompt development of drug candidates that could potentially make the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.